Policy Lead - Clinical Trial Abundance Movement

1Day Sooner represents altruistic medical research participants. We seek to accelerate medical progress by advocating for better ways to generate high-quality human evidence. We are hiring a Policy Lead to drive the policy agenda of our Clinical Trial Abundance (CTA) program. Advances like CRISPR-Cas9, next-generation sequencing, mRNA vaccines, and AI should be enabling a wave of biomedical innovation, but they are bottlenecked by the difficulty and growing expense of testing medicines in humans. Clinical Trial Abundance is the idea that we should make health evidence easier to generate and do more with the evidence we already have. It’s been expounded by thinkers like Ruxandra Teslo , Adam Kroetsch , and Saloni Dattani . The Policy Lead will be responsible for overseeing and managing 1Day’s Clinical Trial Abundance policy development process. The ideas they help develop will feed into regulatory, legislative, and administrative recommendations made by a well-connected and well-resourced movement with access to a range of bipartisan decision-makers. Policy targets for our work include improving Phase 1 trials, IRBs, the use of federal datasets to generate regulatorily relevant real-world evidence, and developing the idea of a right to research.

1Day Sooner represents altruistic medical research participants. We seek to accelerate medical progress by advocating for better ways to generate high-quality human evidence. We are hiring a Policy Lead to drive the policy agenda of our Clinical Trial Abundance (CTA) program. Advances like CRISPR-Cas9, next-generation sequencing, mRNA vaccines, and AI should be enabling a wave of biomedical innovation, but they are bottlenecked by the difficulty and growing expense of testing medicines in humans. Clinical Trial Abundance is the idea that we should make health evidence easier to generate and do more with the evidence we already have. It’s been expounded by thinkers like Ruxandra Teslo , Adam Kroetsch , and Saloni Dattani . The Policy Lead will be responsible for overseeing and managing 1Day’s Clinical Trial Abundance policy development process. The ideas they help develop will feed into regulatory, legislative, and administrative recommendations made by a well-connected and well-resourced movement with access to a range of bipartisan decision-makers. Policy targets for our work include improving Phase 1 trials, IRBs, the use of federal datasets to generate regulatorily relevant real-world evidence, and developing the idea of a right to research.

1Day Sooner is a nonprofit that advocates for people who participate and want to participate in high-impact medical studies.